Keros Therapeutics (KROS) EBIAT (2019 - 2025)
Keros Therapeutics (KROS) has disclosed EBIAT for 7 consecutive years, with -$23.5 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 49.03% year-over-year to -$23.5 million, compared with a TTM value of $87.0 million through Dec 2025, up 146.44%, and an annual FY2025 reading of $87.0 million, up 146.44% over the prior year.
- EBIAT was -$23.5 million for Q4 2025 at Keros Therapeutics, down from -$7.3 million in the prior quarter.
- Across five years, EBIAT topped out at $148.5 million in Q1 2025 and bottomed at -$53.0 million in Q3 2024.
- Average EBIAT over 5 years is -$20.8 million, with a median of -$28.5 million recorded in 2022.
- The sharpest move saw EBIAT crashed 328.21% in 2022, then surged 444.32% in 2025.
- Year by year, EBIAT stood at -$6.9 million in 2021, then plummeted by 328.21% to -$29.7 million in 2022, then crashed by 35.42% to -$40.2 million in 2023, then decreased by 14.37% to -$46.0 million in 2024, then surged by 49.03% to -$23.5 million in 2025.
- Business Quant data shows EBIAT for KROS at -$23.5 million in Q4 2025, -$7.3 million in Q3 2025, and -$30.7 million in Q2 2025.